ACON Investments a private equity investment firm based in Washington, D.C., announced that it has completed the sale of its interest in Vitalis S.A.C.I. and its affiliates, to Laboratorios Sanfer, S.A. de C.V., a Mexican pharmaceutical firm and one of Latin America's largest players in the pharmaceutical space.
Vitalis is a Bogota, Colombia-based manufacturer and wholesaler of injectable pharmaceuticals used and distributed in hospitals, clinics and drug stores across Latin America. Since ACON´s acquisition of Vitalis in 2021, the Company has experienced significant growth illustrated by the expansion of its installed capacity as well as an upgrade of its manufacturing facilities to meet the highest quality environmental and social standards. The Company also broadened its product portfolio with over 700 registered products and strengthened its geographic footprint through the opening of new commercial channels across the region, including an acquisition in Chile. These initiatives positioned the Company as one of the largest suppliers of injectable pharmaceuticals in Latin America.
"This has been a very successful investment for us and exemplifies ACON's disciplined, value-driven strategy and our ability to deliver strong performance despite dynamic market conditions," said Alberto Hernández, Partner at ACON Investments. "Our collaboration with Vitalis showcases ACON's ability to grow businesses across Latin America while working alongside management teams to drive sustainable growth, foster innovation and create lasting social and environmental impact."
This transaction follows ACON's successful exits from Dorí Alimentos S.A. and Conexão Group, ACON portfolio investments in Brazilian companies, which were exited in 2023 and 2024, respectively. ACON has 29 years of experience in Latin America, where it has invested in 44 companies across 10 different countries, 30 of which have been sold to strategic or financial buyers.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox!
Sign up now!